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Opening Session.  Dr. Carla Campbell, the ACCLPP Chair, called the meeting to order 
at 9:05 a.m. on October 15, 2002.  She welcomed the attendees to the proceedings and 
particularly recognized Dr. Patrick Meehan, the new ACCLPP Executive Secretary.  She 
also thanked Mr. Gary Noonan for serving as the former Designated Federal Official 
(DFO).  Mr. Noonan was pleased to have served in this capacity.  He commended 
ACCLPP on its continued effort to eliminate childhood lead poisoning.  Dr. Campbell 
opened the floor for introductions. 
 
Update on National Center for Environmental Health (NCEH) Activities.  Dr. 
Meehan reported that no ACCLPP member had a conflict of interest based on a review 
of all financial disclosure forms submitted.  He announced that the Lead Poisoning 
Prevention Branch (LPPB) was recently moved to the Division of Emergency and 
Environmental Health Services (EEHS).  The National Pharmaceutical Stockpile (NPS) 
is currently housed in EEHS, but the program will soon be transferred to the Office of 
Homeland Security.  LPPB’s new position in EEHS will fill the upcoming vacancy by 
NPS and allow emergency public health and terrorism activities to be more evenly 
distributed throughout NCEH. 
 
The decision to relocate LPPB was also based on EEHS’s strong focus on 
environmental health services.  Lead poisoning has traditionally played a significant role 
in these types of initiatives.  Ms. Linda Anderson will serve as the LPPB Acting Branch 
Chief until the position is permanently filled.  Dr. Meehan presented an organizational 
chart to inform ACCLPP of LPPB’s new location in NCEH and describe EEHS’s six 
branches:  Chemical Demilitarization, Emergency Preparedness and Response, 
Environmental Health Services, International Emergency and Refugee Health, NPS, 
and Vessel Sanitation. 
 
EEHS is charged with providing technical assistance, guidance and support to front-line 
state and local environmental health service providers.  Many new and emerging health 
issues are environmentally-related and require environmental health interventions.  For 
example, lead poisoning, mold, injuries and indoor air quality are all components of 
housing and urban health.  Of the 400,000 to 800,000 children with blood lead levels 
(BLLs) of 10 µg/dL or above, household income, age of housing and other common 
socioeconomic, demographic or housing risk factors have been detected.  Clusters of 
these risk factors have provided NCEH with significant opportunities to identify high-risk 
areas from an epidemiological perspective. 
 
As LPPB is more fully absorbed into EEHS, several activities will be conducted.  First, 
high-risk children with elevated BLLs (EBLLs) will continue to be identified through 
screening.  Second, partnerships with the Women and Infants Children (WIC) Program, 
U.S. Department of Housing and Urban Development (HUD), medical providers and 
other groups will be strengthened to reach at-risk children who have been traditionally 
missed.  Third, a solid follow-up program will be designed to provide children with full 
case management services, i.e., screening, provision of lead-safe housing and 
continued testing.  EEHS will extensively use ACCLPP’s case management guidelines 




Fourth, collaborative efforts will be undertaken with established partners at federal, state 
and local levels to identify high-risk and housing characteristics; immediately abate risks 
through primary prevention; take a holistic approach to housing and health issues; and 
develop local community-based lead elimination plans.  EEHS will soon release the new 
lead poisoning prevention cooperative agreement; the new project cycle begins on July 
1, 2003.  FY’03 grantees will be required to develop lead elimination plans, more clearly 
analyze data to target high-risk areas, and illustrate more progress in eliminating lead 
poisoning.  EEHS will circulate the draft cooperative agreement to outside groups for 
review and comment. 
 
Dr. Piomelli urged CDC to emphasize the responsibility of local public health officers in 
identifying high-risk areas.  Instead of writing prevention papers, CDC should strongly 
encourage public health officers to make field visits and report locations that are lead 
poisoned.  He pointed out that the need for safe houses is omitted from ACCLPP’s 
previous papers.  During remediation, surrounding apartments or homes can become 
contaminated from lead dust.  Dr. Piomelli’s position was that ACCLPP should provide 
education on local residences where children can live during remediation of a lead-
poisoned home.  He encouraged CDC to support this outreach effort. 
 
Dr. Binns inquired about LPPB’s role in EEHS’s existing branches and steps that will be 
taken to ensure lead continues to be a strong priority.  Dr. Campbell was pleased EEHS 
will evaluate housing for risks to children and others.  This activity will support 
ACCLPP’s ongoing efforts in both primary and secondary prevention to improve 
remediation services for homes with environmental hazards. 
 
Dr. Meehan made some follow-up comments in response to ACCLPP’s deliberations.  
CDC will encourage Childhood Lead Poisoning Prevention Programs (CLPPPs) with 
HUD grants in their jurisdictions to use HUD funding for environmental evaluation and 
remediation for any low-income housing.  These dollars can also be used to support 
field visits by public health officers in identifying high-risk areas.  In EEHS, LPPB will 
continue to be structured as a separate entity with an independent branch chief and 
support staff.  At $43 million, LPPB will have more funding than any other EEHS branch.  
LPPB will also be strengthened by the Environmental Health Services Branch and 
Healthy Homes Project.  With LPPB’s funding, considerable size and solid network of 
established partners, lead activities will continue to be a priority within NCEH. 
 
Before opening the floor for the next presentation, Dr. Campbell presented plaques to 
recognize the diligent efforts and accomplishments of Dr. Birt Harvey, the Case 
Management Workgroup Chair, as well as Ms. Anne Guthrie-Wengrovitz, in absentia, 
and Dr. Richard Hoffman, the Medicaid Screening Workgroup Co-Chairs.  The 
attendees applauded the achievements of these ACCLPP members.  Dr. Campbell also 
acknowledged valuable contributions by ACCLPP members whose terms recently 





Case Management Update.  Dr. Harvey outlined the history of the workgroup’s 
activities for the benefit of new members.  ACCLPP acknowledged that a stronger focus 
should be placed on case management due to the collection of new data after the 
publication of CDC’s case management guidance in 1991.  Increased emphasis was 
also needed based on differences among case management recommendations by 
various cities and states.  Experts were selected to advise the workgroup, collect 
supporting data and assist in developing updated case management guidelines.  Drafts 
were presented to ACCLPP for review and comment and then revised based on this 
input.  The final document was recently published and distributed. 
 
To determine impact of the case management document, the workgroup agreed an 
independent contractor should administer surveys to case managers and program 
directors pre- and post-publication.  The survey would be designed to identify case 
management activities at baseline, changes in practice several years after publication 
and problems with the document.  The survey would also provide an opportunity for 
case managers to make recommendations on improving the document.  However, the 
workgroup was informed that approval by the Office of Management and Budget (OMB) 
would be needed for a contractor to interview case managers.  This process typically 
requires six to nine months to complete and would not allow baseline data to be 
gathered. 
 
To overcome this barrier, a telephone interview was administered to only 60 program 
directors in the United States and was conducted by CDC rather than an outside 
contractor.  The interview questions were refined by a contractor and reviewed by the 
workgroup.  Each interview required one to 1.5 hours to complete and focused on five 
case management issues:  nutritional, developmental, environmental, medical and 
educational.  Since the interview was administered to program directors rather than 
case managers in the field, the workgroup acknowledges that responses may not be 
completely accurate.  Key findings from the data analysis of 60 programs surveyed are 
as follow. 
 
 • 37% of programs do not evaluate zinc intake. 
 
• 11 programs provide assistance in WIC enrollment. 
 
• 14 programs conduct follow-up to determine whether WIC benefits were 
received. 
 
• 11 programs never refer a child for a formal developmental assessment by 
a qualified professional.  Of the 49 programs that make referrals, the 
majority are at BLLs which are inconsistent with the recommendations.  
Case management guidelines do not recommend referral unless the BLL 
is >20 µg/dL or other factors influence the child’s development.  Five 
programs routinely make referrals when the BLL is 10 µg/dL; eight 




• 18 programs do not consider any risk factors other than BLLs in deciding 
to evaluate a child, such as prematurity, substance abuse or single 
parenthood. 
 
• 8 programs conduct follow-up after case closure to detect additional 
problems when the child enters school. 
 
• 8 programs recommend that the primary care physician follow-up the child 
with surveillance after case closure. 
 
• 17 programs do not address any further issues with the child after case 
closure. 
 
• 27 programs allow case managers to develop written plans in association 
with care givers to manage a child with a significant EBLL. 
 
• 19 programs recommend that care givers create barriers to keep children 
away from obvious sources of EBLL in the home; 41 programs 
recommend washing hands and toys; 42 programs recommend wet 
mopping floors; 26 recommend wiping window compartments; 11 
recommend leaving shoes at the door; and 7 programs recommend 
placing floor mats at entryways. 
 
• 41 programs list management of lead hazards in the home as a top 
priority. 
 
• 36 programs believe a child’s age is not a factor in prioritizing 
environmental assessment. 
 
• 10 programs do not routinely collect dust wipes as a source of lead dust in 
the home; 53 programs routinely use XRF, which is far less important than 
dust wipes. 
 
• 36 programs always obtain clearance by dust wipes before a child 
reenters the home; 7 programs almost always obtain clearance. 
 
• 52 programs never use power sanding equipment to control lead in the 
home.  Since this method is inappropriate, the 8 programs that use power 
sanding equipment must be educated. 
 
• 48 programs follow up BLLs of 10-14 µg/dL. 
 
• 22 programs recommend a complete history and physical for BLLs <20 
µg/dL.  Unless other risk factors have been identified, this practice is 




• 19 programs routinely test a child for anemia if the BLL is >20 µg/dL. 
 
• 46 programs do not recommend long-bone x-rays; 50 programs do not 
recommend urinalyses and kidney function tests. 
 
• 20 programs recommend that chelation be undertaken for BLLs <45 
µg/dL.  This practice is inappropriate according to the case management 
guidelines. 
 
• 10 programs recommend hospitalization at BLLs <45 µg/dL; 17 programs 
recommend hospitalization at BLLs 45-69 µg/dL; 9 programs do not 
recommend hospitalization at any BLL. 
 
• 41 programs follow up with primary care providers at case initiation; 26 
programs submit summaries of initial evaluations to primary care 
providers; 17 provide primary care providers with case closure reports; 26 
programs alert primary care providers to the potential for future problems. 
 
Overall, the majority of programs adhere to most case management guidelines, but the 
rationale for non-compliance with other case management recommendations should be 
determined.  Programs appear to lack solid communication with primary care providers.  
The survey results emphasize the need for ACCLPP to educate program directors and 
case managers about appropriate actions to take during the case management of 
children. 
 
Dr. Pamela Meyer of NCEH reported on activities to disseminate the case management 
document.  Advance copies were distributed to the authors, CLPPPs, various 
organizations, as well as ACCLPP members, liaisons and ex officio representatives.  
Although 2,000 copies were printed in June 2002, additional requests warranted a 
reprinting of 3,000 copies in July 2002.  The document was also posted on the CDC 
web site.  To publicize the document, communication staff created and distributed 
advertisements to professional journals with a request that the notices be published. 
 
CDC made presentations on the case management guidelines during a lead conference 
and a five-day training session by the Louisville, Kentucky lead program.  The case 
management presentation will be repeated during regional lead conferences, the annual 
program manager training session and other upcoming events in FY’03.  CDC has 
contracted Battelle Memorial Institute (Battelle) to develop a training curriculum, but the 
tool will first be piloted with 30 participants during three initial training sessions.  The 
curriculum will then be evaluated, revised and refined based on input and more widely 
launched during five additional training sessions.  The workshops will be held in various 
regions throughout the country to allow both program directors and case managers to 
attend. 
 
The eight-hour training sessions will cover the five case management areas highlighted 
in the document.  During each workshop, participants will have an opportunity to self-
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assess individual case management practices in small groups and compare current 
activities with the new guidelines.  Responses to questions and concerns raised during 
training sessions will be posted on the CDC web site.  Training materials will be 
developed into a train-the-trainer guidance manual and circulated to all grantees.  CDC 
expects to obtain input on the draft work plan within the next two months, pilot the 
training curriculum in January 2003 and conduct additional training sessions in March 
2003.  CDC is also considering the possibility of designing a web-based training 
program in the future to more effectively meet training needs of grantees. 
 
To determine current case management practices and evaluate impact of the 
document, Battelle will conduct a survey in the next year with a revised version of the 
telephone interview.  Based on the time-line for OMB approval, two surveys may be 
administered to case managers. 
 
ACCLPP weighed in regarding CDC’s case management activities.  Dr. Piomelli 
expressed concern about the manufacturer’s recommendation to use Chemet while a 
child resides in a lead-contaminated home.  He questioned whether the case 
management document clarifies that a child may absorb more lead while taking an oral 
chelator.  Dr. Harvey confirmed that the document clearly recommends removing a child 
from a lead-contaminated home if significant renovations will be made.  Dr. Binns 
encouraged CDC to require grantees under the new lead poisoning prevention 
cooperative agreement to integrate the case management document into programs.  
She also advised CDC to incorporate the case management training sessions into 
existing activities rather than develop an isolated eight-hour module. 
 
Ms. McLaine emphasized the importance of adding language in the new lead poisoning 
prevention cooperative agreement to address funding and resources, particularly for 
Medicaid-eligible children.  Dr. Thompson mentioned that development of online case 
management training sessions could be an additional requirement under the new 
cooperative agreement to address the issue of turnover among case managers.  Dr. 
Hoffman suggested that a feedback graph be designed to allow programs to compare 
and contrast individual practices versus the guidelines.  The chart could be tailored and 
distributed to each of the 60 CLPPPs. 
 
Ms. Murphy added that the CDC project officer should conduct the assessment in 
conjunction with the program director.  When work plans are submitted, the project 
officer can write specific objectives to address case management deficiencies that were 
detected in a particular CLPPP.  Dr. Thompson inquired whether the survey allowed 
CDC to capture variability among CLPPPs and identify the most effective programs in 
reducing BLLs in children.  She noted that obstetricians and gynecologists were 
excluded from the case management document dissemination plan.  These providers 
are in a position to educate women on lead risks prior to giving birth. 
 
Dr. Meyer replied that the telephone interview was anonymous in an effort to obtain 
honest responses.  Although this survey design will not allow CDC to provide input to 
each individual program, general feedback and comments will be distributed.  Dr. 
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Harvey hoped Battelle’s refined survey will capture variability in practices among 
programs, but he welcomed suggestions from ACCLPP members to further address this 
issue.  Dr. Hoffman acknowledged that this methodology is flawed since many program 
directors may not recall their responses and therefore would not apply CDC’s 
recommendations. 
 
Dr. Valerie Charlton, of the California Department of Health Services, was interviewed 
and announced that some survey questions were confusing, particularly dust wipes 
versus XRF.  She also noted that legitimate disagreements or issues can surface from 
the case management guidelines.  For example, the California lead program would 
conduct a complete history and physical on a child with a persistent BLL of 15 µg/dL, 
but the guidelines do not recommend this practice on BLLs <20 µg/dL.  Nevertheless, 
she thanked ACCLPP and CDC for developing, distributing and evaluating the case 
management document.  Dr. Rogan suggested that CDC apply the immunization model 
or use other data as a basis to measure best practices in case management. 
 
Mr. Timothy Morta is an LPPB project officer for the lead poisoning prevention 
cooperative agreement.  He stated that the programs are waiting to receive the new 
guidelines since case management will have a stronger emphasis in the FY’03 
language.  CDC will more closely monitor and track case management activities and 
provide technical assistance based on requests by grantees in quarterly reports.  
CLPPPs are closely collaborating with HUD, the U.S. Environmental Protection Agency 
(EPA), community-based organizations and other local groups to leverage additional 
funding and undertake secondary prevention efforts.  LPPB expects the programs to 
make dramatic changes based on the survey results. 
 
Primary Prevention Update.  Ms. Amy Murphy, the Primary Prevention Workgroup 
Chair, outlined the history of the workgroup’s activities for the benefit of new members.  
Since November 2001, the workgroup has convened several face-to-face meetings and 
conference calls.  During these meetings, the workgroup developed a draft primary 
prevention document that is targeted to childhood lead poisoning prevention and 
housing programs at the local level.  One of the most significant challenges the 
workgroup faced was appropriately addressing housing versus other sources of lead 
exposure. 
 
Based on data from the National Housing And Nutritional Examination Surveys and 
other sources, housing was found to be the major lead exposure source for children and 
will be the primary emphasis of the primary prevention document.  However, other 
sources will be incorporated into the document as well.  After the draft is finalized, a 
strategy will be designed for local programs to effectively implement the document.  The 
final document will be published in professional journals to summarize primary 
prevention recommendations to various audiences, including pediatricians, family 
practitioners and public health professionals.  A web-based questionnaire has also been 
created and will be distributed to lead poisoning list serve members (to collect 




The document will contain a living appendix to illustrate concrete approaches programs 
take to implement primary prevention or use secondary interventions to transition into 
primary prevention.  The workgroup expects to add this component to the document by 
the next ACCLPP meeting.  The workgroup hopes the document will establish a federal 
infrastructure to sustain primary prevention at the local level and create a sense of 
urgency to meet the 2010 goal of eliminating lead poisoning. 
 
For the benefit of new members, Drs. Campbell and Meehan explained the roles of 
workgroups and ACCLPP.  ACCLPP members evaluate and discuss issues that require 
increased emphasis or updated guidance.  Recommendations are then made by 
ACCLPP to establish and charge a workgroup to gather data on a particular issue.  
Because ACCLPP is the parent committee, information collected by workgroups is 
presented to all members for review and comment during public meetings.  Any 
recommendations or documents developed by workgroups are considered as ACCLPP 
products.  ACCLPP members volunteer to serve on workgroups, but outside experts, 
consultants, liaisons and ex officio representatives can serve as well. 
 
Although workgroups are limited to a small number of individuals, a chair is still 
appointed to lead activities.  ACCLPP convenes meetings twice a year, but workgroups 
generally meet by conference calls or face-to-face meetings on a more frequent basis.  
ACCLPP is a discretionary committee that is chartered to provide advice to the HHS 
Secretary and CDC Director.  The operation, management and activities of ACCLPP 
are supported by CDC/NCEH/LPPB.  CDC justified the need for ACCLPP by 
emphasizing the importance of receiving expert advice on childhood lead poisoning 
prevention.  The floor was opened for ACCLPP to provide input and recommendations 
on the primary prevention document. 
 
 General Comments 
• Develop a more concise and succinct document by decreasing the 
number of pages from 19 to five.  Explain the rationale, briefly describe the 
context of primary prevention and list recommendations.  Move all other 
text into an appendix. 
 
• Use the case management document as a model and incorporate 
introductory pages that highlight key points and recommendations for 
each chapter. 
 
• Describe the magnitude of childhood lead poisoning in more detail to 
reach audiences that may not be familiar with this issue.  For example, 
clearly explain why childhood lead poisoning is “a major public health 
problem” at the beginning of the document.  Use more basic terminology 
such as “prevention of lead poisoning of children who live in older 
housing” rather than “primary prevention.” 
 
• Cite references, solid research and data needs to support key statements, 
models and strategies described in the document, such as the HIV Testing 
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Survey that compares prevalence-wide screening data and door-to-door 
samples.  Include epidemiological evidence on EBLLs by region and age 
of housing to strengthen the rationale for focusing the document on 
housing as the primary source of lead exposure.  Present rigorous 
evidence on lead dust exposure and other risk factors in children who 
develop EBLLs to compensate for the lack of data on interventions. 
 
• Explicitly state that variability exists in communities at local, national and 
international levels and between urban and rural environments.  For 
example, some programs may not view housing as a major problem in 
lead exposure. 
 
• Outline a strong approach that authorizes entry into lead-contaminated 
homes and mandates repairs.  Place this language in the “Regulatory 
Infrastructure and Incentives” section.  Reference Massachusetts and 
other states that take civil or criminal actions to enforce compliance with 
lead-safe housing standards.  Add these examples to the living appendix. 
 
• Ensure that ACCLPP’s position on primary prevention is emphasized in 
the document by listing recommendations on a particular issue at the end 
of each chapter. 
 
• Acknowledge that primary prevention efforts will differ based on variability 
among private, public or rental housing stock. 
 
• Recommend that fiscal incentives be provided to property owners who 
reduce risks by complying with lead-safe housing standards. 
 
• Develop a transparent process to clearly identify homes with lead hazards 
when a regulatory public health approach is taken. 
 
• Take a strong primary prevention position by advocating the elimination of 
lead into the environment by industries that can economically and viably 
make substitutions. 
 
• Clearly identify target audiences, messages, expected outcomes and the 
most effective delivery methods of the document.  For example, target the 
document to reach legislators who protect children. 
 
• Maintain a narrow focus on housing as the primary source of lead 
exposure; create a companion document to focus on non-housing 
sources. 
 
• Recommend that pediatricians be an active component in the primary 
prevention process when birth certificates are issued or when high-risk 




• Cite the recommendation in the case management document that 
supports temporary relocation of families when a home is being 
remediated and a child has been identified with an EBLL. 
 
• Obtain CDC’s full endorsement of the document to ensure credibility, 
support, cooperation and implementation by EPA, HUD and other 
agencies.  For example, ACCLPP could present its primary prevention 
guidelines to the Federal Interagency Task Force on Children’s 
Environmental Health. 
 
• Incorporate guidance to empower individuals to identify risk factors and 
immediately become involved in the primary prevention process. 
 
• Delete “secondary prevention” and “tertiary prevention” throughout the 
document.  Focus on the window of opportunity to prevent lead exposure 
during a young child’s development. 
 
• Add strong and clear recommendations from ACCLPP about the need for  
local housing programs and non-HHS agencies to provide adequate 
resources for primary prevention. 
 
• Ensure that the FY’03 lead poisoning prevention cooperative agreement 
contains language for CLPPPs to play a leadership role in both primary 
prevention and overall childhood lead poisoning prevention.  Achieve this 
goal by providing CLPPPs with adequate information to make appropriate 
decisions and evaluate priorities at the local level. 
 
• Add “health departments” and other appropriate agencies to each 
reference of CLPPPs in the document. 
 
• Add supporting data to illustrate the cost effectiveness of primary 
prevention interventions described in the document. 
 
 Specific Comments 
• Page 1:  Develop and include a three-page executive summary to 
highlight the key points of the document for non-technical audiences. 
 
• Page 3:  Review data cited in the second and third paragraphs because 
this information is not consistent with data previously reported by Dr. 
David Jacobs of HUD. 
 
• Page 4:  Delete references to the Treatment of Lead-Exposed Children 




• Page 4:  Add “were chelated” after the first phrase in Section II(2) to make 
a complete sentence. 
 
• Page 4:  Include comparative data to the finding of a ”24% decline in 
children’s BLLs after paint abatement was completed.” 
 
• Page 4:  Revise the “Rationale for Primary Prevention” section to focus 
more on the importance of prevention exposure, i.e., longevity of lead in 
the human body and the inability to reverse damage caused by lead. 
 
• Page 4:  Describe effective strategies to strengthen the “Rationale for 
Primary Prevention” section.  Revise the text to be evidence-based. 
 
• Page 10:  Delete paragraphs 2-5 under the “Options for targeting high-risk 
families with young children” section.  Detailed descriptions of these 
programs are unnecessary for a primary prevention document; the options 
can be summarized in one sentence. 
 
• Page 12:  Decrease the “Existence of Comprehensive Secondary 
Interventions” section from three paragraphs. 
 
• Page 12:  Modify ACCLPP’s recommendation for “HHS and DOA to fund 
research and demonstration projects” to encourage CDC to immediately 
undertake this activity in the FY’03 lead poisoning prevention cooperative 
agreement. 
 
• Page 12:  Add language to more strongly emphasize condition of paint, 
maintenance, housekeeping and other basic housing factors in the 
“Development of an Evidence-Based, Cost-Effective Lead Safe Housing 
Standard” section. 
 
• Include data in the “Development of an Evidence-Based, Cost-Effective 
Lead Safe Housing Standard” section to assist CLPPPs or health 
departments in making a stronger case when requesting resources from 
other agencies.  For example, the information could contrast costs for 
primary prevention versus treatment of EBLLs. 
 
• Page 17:  Revise the “Collaboration with Multiple Stakeholders” section to 
be more realistic.  CDC can achieve this goal by convening a primary 
prevention workshop with potential collaborators to discuss interests, 
issues, lessons learned and best practices of local groups. 
 
• Other:  Add an appendix citing the scientific literature to support the 




On behalf of Dr. Richard Jackson, the NCEH Director, Mr. Robert Delaney welcomed 
ACCLPP members, liaisons and ex officio representatives to the meeting.  He 
emphasized the importance of ACCLPP and recognized its valuable contributions, 
guidance, efforts and recommendations in preventing childhood lead poisoning.  To 
further contribute to the significant reduction of the childhood lead poisoning burden in 
the United States, CDC has undertaken collaborative efforts with federal agencies, 
industry, professional organizations and advocacy groups. 
 
However, established partnerships must be strengthened to reach special populations 
of children who remain a major public health concern, i.e., those living in older housing 
with lead paint and lead-contaminated dust and those who are still at high risk for lead 
exposure.  These partnerships must also be maintained to apply the best science, 
strengthen current programs and develop new strategies to eliminate childhood lead 
poisoning as a threat to children in the United States.  Childhood lead poisoning will 
remain a top priority within NCEH.  CDC looks forward to its continued collaboration 
with ACCLPP in significantly contributing to one of the most important public health 
success stories of the decade. 
 
Federal Advisory Committee Act (FACA) Procedures.  Ms. Helen Kuykendall, of the 
CDC Management Analysis and Services Office (MASO), explained that FACA was 
enacted on October 6, 1972 under Public Law 92-463 as a system to create and 
operate advisory committees in the Executive Branch of the federal government.  
Congress created FACA to enhance accountability of advisory committees to the public; 
protect against undue influence of special interest groups; and reduce wasteful 
expenditures of public funds.  Advisory committees are defined by FACA as “any 
committee, board, commission, council, conference, panel or task force established or 
utilized by the federal government for the purpose of obtaining consensus advice or 
recommendations on issues or policies.” 
 
Three types of groups can be chartered under FACA.  A discretionary committee is 
established at the discretion of the agency head; a non-discretionary committee is 
mandated by legislation or statute; and a presidential committee is created by the 
President or Congress.  Committees subject to FACA are established or controlled by 
the federal government; have other than full- or part-time federal employees; provide 
consensus advice; and have a specific purpose, organized structure and fixed 
membership.  “Consensus advice” has not been defined by FACA or the General 
Services Administration (GSA) Final Rule.  For purposes of HHS advisory committees, 
however, consensus is generally defined as a common viewpoint among members 
rather than advice from one individual. 
 
FACA requires advisory committees to have a charter, public access and balanced 
membership in terms of points of view represented and functions to be performed.  
Advisory committee meetings must be announced in the Federal Register at least 15 
days prior to the proceedings.  The public must be allowed to speak or file written 
statements during these sessions.  Detailed minutes must be created and maintained 
for each advisory committee meeting.  The documents must contain the meeting date 
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and location; an attendee list; complete and accurate descriptions of discussions and 
conclusions; and advice or recommendations provided by the committee.  Meeting 
minutes must be completed and submitted to the CDC Committee Management Office 
(CMO) within 90 days after the proceedings. 
 
Verbatim transcripts are also created and maintained for some advisory committees, but 
this document is not required by FACA and cannot substitute detailed minutes.  Working 
papers, transcripts, drafts and all other materials shared among an advisory committee 
must be made available for public inspection as long as the group exists.  ACCLPP is a 
discretionary committee chartered to (1) provide advice and guidance to the HHS 
Secretary, HHS Assistant Secretary for Health (ASH) and CDC Director regarding new 
scientific knowledge, technological developments and practical implications for 
childhood lead poisoning prevention efforts; (2) review and regularly report on childhood 
lead poisoning prevention practices; and (3) recommend improvements in national 
childhood lead poisoning prevention efforts.  MASO is responsible for assisting 
ACCLPP in conducting its business and meeting FACA objectives. 
 
ACCLPP is governed by FACA, the GSA Final Rule and departmental and agency 
policies.  FACA requires advisory committee charters to be renewed every two years or 
the group will be terminated.  MASO consults with HHS, GSA and the Office of General 
Counsel (OGC) to explain the need to continue ACCLPP and describe a plan to ensure 
fairly balanced membership.  Charter renewals must be filed with the GSA Secretariat, 
standing committees of Congress with legislative jurisdiction over agencies and the 
Library of Congress.  The renewal notice must be published in the Federal Register 
when filed. 
 
In addition to the parent advisory committee, subcommittees or workgroups can be 
established to conduct business.  Subcommittees are members from the advisory 
committee who report to the parent committee and are subject to FACA procedures.  
Non-members can serve as consultants to subcommittees if additional expertise is 
needed.  Workgroups are two or more members from the parent committee or 
subcommittee who gather information, conduct research, analyze facts or address an 
issue on a short-term basis.  Workgroups report to the parent committee or 
subcommittee and are not subject to FACA requirements.  However, all workgroup 
activities must be presented to the parent committee or subcommittee and discussed in 
an open session. 
 
Advisory committees are structured with three components.  First, the DFO or Executive 
Secretary supervises day-to-day operations of the advisory committee; approves 
meeting agendas; attends all committee meetings; and ensures all meeting notices are 
published in the Federal Register.  Second, the chair presides over committee 
meetings; determines the operation of meetings in conjunction with the DFO; ensures 
public participation; and certifies the accuracy of meeting minutes.  The chair is selected 
by the agency or members and also serves as a committee member.  Third, committee 
members represent fairly balanced points of view; are appointed as special government 
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employees (SGEs) and must comply with conflict of interest statutes.  Members serve 
overlapping four-year terms up to four years. 
 
FACA defines an SGE as a private citizen appointed by the agency head, HHS 
Secretary or President.  Appointments are based on an individual’s expertise that will 
contribute to the objectives of the advisory committee.  Members serve with or without 
compensation for 130 days or less per year.  Members are appointed to express 
personal opinions only, but are held legally accountable for ethical issues and financial 
interests.  Members must complete and update all required appointment papers and 
financial disclosure forms; review and comply with standards of ethical conduct for 
employees of the Executive Branch; attend all meetings; and actively contribute to 
advisory committee discussions, deliberations and recommendations. 
 
The membership of advisory committees can also contain other individuals.  An ex 
officio is typically a federal employee with full voting rights unless prohibited by statute.  
ACCLPP ex officios are currently non-voting members, but voting rights will be granted 
to these members when the charter is renewed in 2003.  Liaisons represent a particular 
organization on an advisory committee and have no voting rights.  Special consultants 
are invited to serve on advisory committees if additional expertise is needed. In terms of 
FACA management and communications, working relationships are established 
between the advisory committee and DFO; CMO and DFO; and OGC and CMO.  
Recommendations of advisory committees are communicated to the CDC Director and 
eventually forwarded to the HHS Secretary.  Annual reports of advisory committees are 
submitted to Congress by GSA. 
 
A videotape was presented to further orient the new members on conflict of interest, 
legal responsibilities of SGEs, financial disclosures and other FACA procedures.  
Additional information on FACA as well as meeting minutes and annual reports for 
ACCLPP and other advisory committees can be accessed at 
www.gsa.gov/committeemanagment.  Annual reports outline operating costs, projected 
expenditures, membership and frequency of meetings.  Chapter 9 of the HHS General 
Administration Manual contains policies governing advisory committees and can be 
accessed at www.psc.gov/hhsmanuals.html. 
 
Dr. Meehan confirmed that he would closely collaborate with Dr. Campbell to more 
effectively communicate, disseminate and implement ACCLPP’s recommendations 
throughout HHS.  ACCLPP guidance is typically submitted to the HHS Secretary and 
returned to the DFO for a response.  With the new process, recommendations will also 
be forwarded to the CDC Director and HHS ASH.  For example, Dr. Meehan plans to 
telephone the HHS ASH and discuss ACCLPP’s document on targeted screening for 
young children enrolled in Medicaid.  At the invitation of the HHS ASH, Dr. Meehan, an 
ACCLPP member and a representative from the Centers for Medicare and Medicaid 
Services will discuss the document in more detail during a face-to-face meeting.  In the 
future, ACCLPP communications will be submitted on CDC letterhead since EEHS 





Public Comment Period.  A letter from Ms. Renee Robin, the California Director of the 
Children’s Environmental Health Network, was submitted into the public record.  The 
letter expresses the group’s disappointment and concern that the HHS Secretary 
overruled CDC’s recommendations for ACCLPP nominees.  The document is appended 
to the minutes as Attachment 1. 
 
Dr. Charlton announced that a bill was recently passed in California which makes the 
presence of deteriorated lead-based paint, lead-contaminated dust, lead-contaminated 
soil and other lead hazards violations of the housing code.  Local environmental and 
health agencies have been authorized to distribute cease and desist orders in relation to 
these lead hazards.  The new law does not specify age of housing.  The legislation can 
be accessed at www.leginfo.ca.gov. 
 
Dr. Piomelli submitted a letter from Attorney David Schoenbrod into the public record.  
The document asks ACCLPP to reconsider the definition of “lead poisoning” as 
childhood BLLs >10 µg/dL.  The letter is dated April 24, 1996 and was addressed to Dr. 
Henry Falk, the ACCLPP Executive Secretary at that time.  Dr. Piomelli reported that 
the letter was never distributed to ACCLPP.  The document is appended to the minutes 
as Attachment 2. 
 
There being no further discussion, Dr. Campbell adjourned the ACCLPP meeting at 
5:15 p.m. on October 15, 2002. 
 
♦   ♦   ♦  
 
Update by the Review of Evidence for Effects at Low BLL  Workgroup.  Dr. 
Campbell reconvened the ACCLPP meeting at 9:00 a.m. on October 16, 2002 and 
opened the floor to the first presenter.  Dr. Michael Weitzman, of the University of 
Rochester, joined the meeting via conference call.  Although his term has expired, he 
will continue to chair the workgroup that was charged by ACCLPP to review existing 
data on potential adverse effects in children from lead exposure at levels <10 µg/dL.  
The workgroup has maintained constant communication and was successful in 
engaging all outside experts who were asked to assist in this effort.  The workgroup 
welcomes input and recommendations from ACCLPP on the process that has been 
established to review evidence on low BLL effects. 
 
Dr. Tom Matte of NCEH clarified that neither ACCLPP nor the workgroup is charged to 
take action on BLLs <10 µg/dL.  To date, the workgroup has compiled its membership; 
identified outside experts to answer scientific questions; and selected Battelle to 
manage the literature, retrieve data, facilitate logistics, summarize results and support 
other activities.  The workgroup members represent expertise in clinical pediatrics, 
neuropsychological assessment, environmental epidemiology, lead-related 
developmental neurotoxicity, biostatistics, quantitative risk assessment and laboratory 
science.  During the literature retrieval process, the workgroup primarily focused on 




The workgroup agreed that animal studies will not sufficiently answer questions related 
to dose response at a specific range of BLLs.  Evidence the workgroup collected to date 
measures one or more health outcomes.  The initial bibliography was limited to 
toxicological profiles developed by the Agency for Toxic Substances and Disease 
Registry, but the database is now being supplemented with additional literature 
searches and studies that are in press or will soon be published.  To fulfill its charge and 
evaluate dose response, the workgroup has focused on high-relevance articles with a 
large number of study participants with BLLs <10 µg/dL. 
 
To date, only a small number of studies have published results that are directly relevant 
to health effects at BLLs <10 µg/dL.  Other data clearly show a large number of children 
in the population with BLLs <10 µg/dL, but these published reports do not include 
statistical analyses to differentiate between children with BLLs greater or less than 10 
µg/dL.  The workgroup will focus on “type A” studies or published data.  No plans have 
yet been made to focus on “type B” studies in which investigators may be able to 
access raw data.  The workgroup will review and classify the quality of data from cross-
sectional or cohort studies. 
 
During the workgroup’s two conference calls in August 2002, several scientific issues 
were discussed, but not resolved.  These challenges include a process to summarize 
highly relevant evidence; an effective methodology to identify age, secular and seasonal 
trends of BLLs; and the time-line of the workgroup’s published report or policy 
recommendations versus activities by a consortium that has been assembled to conduct 
a pooled re-analysis of raw data from cohort studies and other investigations. 
 
Both CDC and the National Institute of Environmental Health Sciences are providing 
funds to support the pooled re-analysis group.  Dr. Bruce Lanphear serves as the 
principal investigator of the consortium; Drs. David Bellinger and Joel Schwartz serve 
on the group as well.  The workgroup will continue to hold monthly conference calls and 
will also convene a face-to-face meeting in November 2002 to review high-relevance 
type A articles identified to date.  The workgroup hopes to complete an outline of a draft 
report in February 2003 and then finalize and present the document to ACCLPP in late 
spring 2003. 
 
ACCLPP commented on the workgroup’s activities.  Dr. Binns was pleased the 
workgroup is separating studies in which BLLs were measured in very young children 
versus older cohorts.  This approach will be key in answering scientific questions.  She 
suggested that the workgroup advance beyond the development of an ACCLPP report 
and generate a paper citing current published data on adverse effects at low BLLs.  Dr. 
Matte confirmed that the workgroup is charged with generating an ACCLPP-endorsed 
product suitable for publication in the peer-reviewed literature. 
 
In terms of challenges, Dr. Binns encouraged the workgroup to continue its progress in 
finalizing a summary statement by late spring 2003.  The time-line should not be 
influenced by activities of the pooled re-analysis consortium since this group may not be 
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in a position to publish results for quite some time.  On the one hand, several ACCLPP 
members agreed with Dr. Binns that the workgroup should maintain communication with 
the pooled re-analysis consortium and be aware of its activities without compromising or 
delaying the workgroup’s independent effort.  This goal can be achieved by inviting 
members of the pooled re-analysis consortium to present a status report at a future 
ACCLPP meeting. 
 
On the other hand, Dr. Hoffman saw the benefit in ACCLPP reviewing data collected by 
the pooled re-analysis consortium prior to publication.  He indicated that some ACCLPP 
members may be asked to write an editorial or serve as peer reviewers of the pooled re-
analysis.  Dr. Meehan explained that any ACCLPP member can serve in this capacity 
so long as views are expressed from an individual rather than committee perspective. 
 
Dr. Piomelli acknowledged that the workgroup is addressing a controversial issue.  He 
was disturbed that Drs. Bellinger and Schwartz serve on the workgroup, but have 
published data on adverse health effects at BLLs <20 µg/dL.  Some conclusions 
reached in these studies have been criticized by many experts as “absurd,” “non-
scientific” and “unsupported by statistics.”  Dr. Piomelli strongly recommended that an 
individual  be appointed to serve on the workgroup who does not believe, a priori, major 
adverse effects will occur at low BLLs.  Four workgroup members are neutral on this 
issue; two are, a priori, in favor of the finding that adverse effects at BLLs <10 µg/dL are 
insignificant.  He was concerned that if lead poisoning is defined as all children with 
BLLs <10 µg/dL, the population of children with actual lead poisoning will be forgotten. 
 
Dr. Matte pointed out that some workgroup members are credible and established 
investigators with solid scientific credentials and extensive backgrounds in lead 
developmental neurotoxicity.  Other workgroup members bring an innovative 
perspective to the field.  He was confident that the workgroup represents balanced 
perspectives and will be able to support conclusions.  Dr. Meehan added that Dr. David 
Savitz is a workgroup member who completed a seminal study on electromagnetic 
fields.  In this investigation, Dr. Savitz was extremely objective on another controversial 
subject.  Dr. Harvey clarified that the workgroup is only charged with summarizing and 
presenting data to ACCLPP.  Recommendations on policy issues will be made by 
ACCLPP rather than the workgroup.  No other ACCLPP member expressed concern 
with the workgroup members. 
 
ACCLPP Current Business.  Drs. Campbell and Meehan provided a status report on 
recent ACCLPP communications.  ACCLPP’s August 23, 2002 letter to the HHS 
Secretary requested assistance in ensuring continued research to identify effective 
methods for reducing children’s exposure to lead and other environmental hazards.  
ACCLPP also asked the HHS Secretary to fully support and be actively engaged in a 
study by the National Academy of Sciences (NAS).  This activity will examine ethical 
issues that may arise while conducting research to eliminate housing-related conditions 




A member of the NAS expert panel has been invited to attend a future ACCLPP 
meeting and provide a status report on this activity.  Dr. Meehan will follow up with the 
HHS Secretary’s office to determine the status of a response to ACCLPP’s letter.   
 
ACCLPP’s September 23, 2002 letter to the HHS Secretary discussed the potential 
public health problem of lead poisoning among adopted and refugee children.  To 
educate parents of immigrants and adopted children from overseas on the need for lead 
screening, ACCLPP asked the HHS Secretary to disseminate information to the U.S. 
Department of State and HHS agencies.  To facilitate this process, ACCLPP attached to 
sample one-page letters that can be distributed to parents.   (include info. below in 
same paragraph)Dr. Meehan reported that a response to the letter by the HHS 
Executive Secretary is forthcoming.  He committed to submitting the letter to CDC’s 
Division of Quarantine (DQ) to obtain feedback, background data and guidance on 
effective approaches to address this issue.  DQ has responsibility for medical screening 
of refugees and immigrants.   
 
ACCLPP’s September 26, 2002 letter to the HHS Secretary contained evidence-based 
recommendations on targeted lead screening for young children eligible for Medicaid 
services.   (include info. below in same paragraph) 
Dr. Meehan asked ACCLPP to consider effective strategies to bring the 
recommendations to the attention of CMS.  CDC policy staff will review CMS’s original 
proposal for targeted lead screening as well as the December 2000 Morbidity and 
Mortality Weekly Report that contains ACCLPP’s commitment to produce a document 
on this subject.  The information will then be presented to CMS in an effort to identify 
next steps in the process.  Dr. Meehan confirmed that he will contact CMS within the 
next 30 days. 
 
ACCLPP New Business.  The members suggested several items to be placed on 
future agendas. 
 
• Discussion of ACCLPP’s definition of “lead poisoning.”  
• Discussion of ACCLPP’s priorities. 
• Overview by CDC on the 60 CLPPPs and LPPB’s research priorities to 
ensure children not covered by CLPPPs are not being missed. 
• Discussion or formal review on the impact of ACCLPP’s guidelines and 
recommendations. 
• An orientation to inform new members on the proper procedure to ask for 
presentations, respond to requests and select priorities. 
 
Requests were also made for CDC to provide new members with the following 
information:  the list of topics from which ACCLPP selected its priorities in 2001; a list of 
current ACCLPP members; and a description of current members and charges of 
workgroups.  Dr. Campbell reported that core activities by the Case Management and 
Targeted Screening Workgroups are complete.  The two workgroups no longer convene 
meetings since only follow-up activities are outstanding.  The Primary Prevention and 
Evidence on Low BLL Effects Workgroups are active and made presentations during 
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the meeting.  Updates from these workgroups will continue to be placed on future 
agendas until the respective charges have been fulfilled. 
 
In addition to regular status reports by workgroups, other items are placed on future 
agendas by suggestions from members.  Formal motions that are made and passed by 
voting members are eventually forwarded to the HHS Secretary.  Other agenda items 
include updates on new data, results and interventions in the childhood lead poisoning 
prevention field.  Dr. Campbell encouraged members to suggest future agenda items at 
least one month prior to a meeting. 
 
Public Comment Period.  The Chair opened the floor for public comments; no 
attendees responded. 
 
Closing Session.  The 2003 ACCLPP meetings will be held on March 18-19 and 
October 14-15.  EEHS will confirm these dates by circulating an e-mail message to all 
members. 
 
There being no further discussion, Dr. Campbell adjourned the ACCLPP meeting at 
10:30 a.m. on October 16, 2002. 
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